
【CLAIMS】

【Claim 1】

A formulation for oral administration comprising a compound of (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide of Formula 1 or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose,

wherein the formulation is a tablet:

[Formula 1]



【Claim 2】

The formulation for oral administration according to claim 1, wherein the disintegrant is contained by 1 to 20 wt% with regard to the total weight of the

formulation.

【Claim 3】

The formulation for oral administration according to claim 1, wherein the low-substituted hydroxypropylcellulose is that a substitution degree of a hydroxypropoxy group amounts to 5 to 16 mass%.

【Claim 4】

The formulation for oral administration according to claim 1, wherein the formulation further comprises at least one selected from the group comprising a binder, a filler and a lubricant.

【Claim 5】

The formulation for oral administration according to claim 4, wherein the binder is at least one selected from the group comprising starch, microcrystalline cellulose, colloidal silicon dioxide, mannitol, lactose, polyethylen glycol, polyvinyl pyrrolidone co-polymer, hydroxypropyl cellulose, gelatin and a mixture thereof.

【Claim 6】

The formulation for oral administration according to claim 4, wherein the filler

is at least one selected from the group comprising lactose, microcrystalline cellulose, mannitol and colloidal silicon dioxide.

【Claim 7】

The formulation for oral administration according to claim 4, wherein the lubricant is at least one selected from the group comprising stearic acid, magnesium stearate, calcium stearate, sodium benzoate, sodium stearyl fumarate, glyceryl monooleate, glyceryl monostearate, glyceryl behenate, glyceryl palmitostearate, zinc stearate and a paraffin group.

【Claim 8】

The use of a formulation comprising a compound of (S)-4((5,7-difluorochroman-4-yl)oxy)-N,N-2-trimethyl-1H-benzo[d]imidazole-6-carboxamide of Formula 1 or a pharmaceutically acceptable salt thereof; and at least one disintegrant selected from the group consisting of croscarmellose sodium, sodium starch glycolate and low-substituted hydroxypropylcellulose for oral administration,

wherein the formulation is a tablet:

[Formula 1]

